Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Capecitabine
Xeloda
Routinely available
Local application
29/03/2023
Indication
Adjuvant use following potentially curative surgery for adenocarcinoma of the pancreas to replace 5FU/folinic acid given according to the Mayo schedule
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
-
Comments
-